Customized mannose-conjugated LNP development services for macrophage-targeted delivery, dendritic cell uptake studies, CD206/MR-related targeting validation, ligand density optimization, and payload-compatible formulation screening.
Mannose-conjugated LNPs are lipid nanoparticle (LNP) delivery systems with mannose ligands displayed on the particle surface. These mannose ligands can specifically recognize mannose receptors on target cells, thereby enhancing the targeted delivery ability of LNPs. Mannose receptor-expressing cells include macrophages, dendritic cells, antigen-presenting cells, Kupffer cells, and CD206+ tumor-associated macrophages. Therefore, mannose modification can give LNPs clearer cell-targeting guidance.
With rational design, mannose modification can be combined with PEGylation to support the targeting potential and immune-related functions of LNPs while improving the biological interface of the particle surface. This surface engineering strategy can help regulate protein corona composition, reduce non-specific clearance by the reticuloendothelial system, and improve circulation behavior and delivery efficiency to some extent.
BOC Sciences is committed to helping pharmaceutical and biotechnology researchers develop mannose-modified lipid nanoparticles for the delivery of siRNA, mRNA, circRNA, guide RNA/mRNA complexes, proteins, peptides, small molecules, and imaging payloads. Our services cover mannose ligand design, LNP surface modification, core formulation integration, physicochemical characterization, and target-cell delivery evaluation, helping clients build more stable and more targeted mannose-modified LNP delivery systems.
Mannose Modified LNP Surface Structure IllustrationBOC Sciences supports the full development workflow from mannose ligand engineering to LNP preparation, characterization, and CD206/MR-related targeting evaluation.
We design and prepare mannose-containing lipid components for targeted LNP formulation. The design can be adjusted by mannose valency, linker length, lipid anchor, and surface display strategy.
We introduce mannose ligands onto LNPs using formulation-compatible methods. The method is selected according to payload type, target cell, expected ligand density, and the stability needs of the LNP system.
Mannose modification can change particle assembly, surface charge, RNA loading, and colloidal stability. We optimize the core formulation and the mannose surface layer together, not as separate steps.
We characterize mannose-modified LNPs to confirm particle quality, ligand incorporation, payload retention, and formulation consistency. These data help clients compare formulation candidates with clear decision points.
We evaluate whether mannose modification improves uptake and payload function in relevant cell models. We also design control groups to help separate mannose-related uptake from general nanoparticle uptake.
BOC Sciences supports process development for mannose-modified LNPs. We help improve preparation consistency, ligand insertion efficiency, payload retention, and batch-to-batch comparability.
BOC Sciences supports a wide range of mannose ligand structures and coupling technologies to help researchers build LNP systems with improved receptor accessibility, particle stability, and payload compatibility. Based on each project's payload type, target cell model, and delivery objective, we help clients select suitable ligand and coupling options for Mannose-LNP development.
We support different mannose ligand formats for Mannose-LNP development, from simple monovalent mannose to multivalent and stability-enhanced mannose derivatives.
| Ligand Type | Structural Features | Receptor Affinity Features | Typical Applications |
|---|---|---|---|
| Monovalent Mannose | Single-copy mannose-lipid structure. | Low affinity, usually in the mM range. Higher surface density may be needed. | Basic proof-of-concept studies and low-density surface modification. |
| Trivalent Mannose Cluster, Man3 | Three-arm mannose display based on a lysine scaffold. | Medium affinity, usually in the μM range. Multivalent display can improve receptor interaction. | Adjuvant-related research and dendritic cell-targeted delivery studies. |
| Tetravalent Mannose Cluster, Man4 | Four-arm mannose display based on dendritic or cyclodextrin-like scaffolds. | Medium to high affinity, usually in the μM range. | Tumor-associated macrophage, or TAM, reprogramming research. |
| High-Valency Mannose, Man8-Man16 | Multivalent mannose display using dendritic polymers or nanoparticle-based scaffolds. | High apparent affinity, usually in the nM to μM range, with strong multivalent effects. | Immune activation studies and lymph node-targeted delivery research. |
| Thio-Mannose | O-glycosidic linkage replaced by a thioglycosidic linkage. | Improved metabolic stability. | Long-term in vivo research and repeated-dose study designs. |
| Fluoro-Mannose | Hydroxyl groups are replaced or modified with fluorine-containing groups. | Better resistance to glycosidase-related degradation. | Mannose-LNP systems that need stronger ligand stability. |
We develop mannose coupling and incorporation methods according to the LNP composition, payload type, target ligand density, and expected surface stability.
| Coupling Strategy | Service Subtype | Chemical Principle | Suitable Use Cases |
|---|---|---|---|
| Lipid Anchoring | Mannose-cholesterol insertion | Mannose-cholesterol is inserted into the LNP lipid layer through hydrophobic interaction. | Fast and mild modification, but insertion efficiency may be limited. |
| Mannose-DSPE/DSPC co-assembly | Mannose-phospholipids act as structural lipids during LNP assembly. | Higher stability and more controllable mannose orientation. | |
| PEG Bridging | Man-PEG2000-DSPE post-insertion | PEG provides flexibility and spatial freedom for mannose display. | Common method to balance particle stability and receptor accessibility. |
| Man-PEG54-DSPE short-chain bridging | Short PEG reduces surface shielding effects. | Useful for high mannose density needs and immune-cell activation studies. | |
| Covalent Coupling | Thiol-maleimide coupling | Mannose-thiol reacts with Mal-PEG-lipid on the LNP surface. | High selectivity. Reaction pH needs to be controlled. |
| DBCO-azide copper-free click chemistry | Mannose-azide reacts with DBCO-PEG-lipid on the LNP surface. | Bioorthogonal and copper-free surface coupling. | |
| Reductive amination | Aldehyde-functionalized mannose reacts with amine groups on the LNP surface. | Classical coupling method, but the reaction condition can be relatively harsh. | |
| Non-Covalent Affinity Assembly | Biotin-streptavidin bridging | Modular and reversible assembly through biotin-streptavidin interaction. | Rapid screening and proof-of-concept mannose display studies. |
Develop mannose-modified LNPs with optimized ligand exposure, payload loading, particle quality, and macrophage/DC-related delivery performance.
Mannose-modified LNPs combine receptor-precision targeting with innate immune modulation—delivering payloads to dendritic cells and macrophages via CD206/DC-SIGN recognition, while avoiding the immunogenicity risks of antibody conjugates and the screening costs of aptamers.
Precision Immune-Cell Targeting
Surface mannose ligands engage C-type lectin receptors—primarily CD206 (mannose receptor) on dendritic cells and macrophages, and DC-SIGN on specific DC subsets. This receptor-mediated uptake directs LNPs toward professional antigen-presenting cells while bypassing non-target tissues. Multivalent mannose clusters (Man3–Man16) exploit avidity effects to achieve nanomolar-range apparent affinity, enabling selective targeting of M2-polarized tumor-associated macrophages (TAMs) that overexpress CD206.
Low-Immunogenicity, Scalable Ligand
Mannose is an endogenous monosaccharide with established metabolic pathways (mannose kinase → glycolysis), eliminating the anti-drug antibody (ADA) risks associated with proteinaceous ligands. Unlike antibodies (~150 kDa, cell-culture production) or aptamers (SELEX-dependent, batch-variable), mannose-PEG-lipid conjugates are fully synthetic with precise batch-to-batch consistency, straightforward analytical characterization (HPLC/MS), and scalable manufacturing at significantly lower cost-of-goods.
Robust Formulation & Manufacturing Compatibility
Mannose-PEG-DSPE integrates seamlessly into standard microfluidic workflows (IJM, SHM) and ethanol-dilution protocols without reformulating core ionizable lipid ratios. The neutral/weakly anionic ligand does not interfere with pH-dependent charge-flip mechanisms. Optimized formulations maintain >90% encapsulation efficiency post-modification, and mannose itself contributes lyoprotectant properties that simplify lyophilization cycles—supporting direct scale-up from screening batches to larger preparation batches.
Tunable Immune Modulation
Mannose density functions as a rheostat for immune polarity: low-density surfaces favor liver sinusoidal endothelial cell (LSEC) uptake and regulatory T-cell (Treg) induction for tolerance protocols; high-density/multivalent configurations activate Syk-CARD9 signaling in dendritic cells, driving IL-12 and TNF-α secretion for adjuvant-like Th1/CTL priming. This ligand-programmable switch enables a single platform to address both autoimmune diseases (tolerance) and infectious disease or cancer vaccines (activation).
BOC Sciences develops mannose-modified LNPs for many payload types used in macrophage, dendritic cell, APC, and CD206-related delivery research. Each payload needs a suitable loading strategy, particle design, and functional readout. We help match mannose surface engineering with the payload type and the target-cell model.
| Payload Type | Supported Uses & Mannose-LNP Development Considerations | Request Information |
|---|---|---|
| Mannose-LNP Development for siRNA | Suitable for macrophage-related gene-silencing studies, tumor-associated macrophage modulation, and inflammatory pathway research. Development focuses on siRNA encapsulation, free RNA reduction, mannose density, CD206-related uptake, and knockdown comparison using matched control LNPs. | Inquiry |
| Mannose-LNP Development for mRNA and Reporter RNA | Designed for reporter expression, protein expression, antigen-related delivery, and formulation comparison studies. Development considers mRNA integrity, encapsulation efficiency, mannose surface exposure, particle stability, and expression readouts in macrophage or dendritic cell models. | Inquiry |
| Mannose-LNP Development for circRNA and Self-Amplifying RNA | Applicable to RNA delivery systems that need strong payload protection and target-cell expression. BOC Sciences supports lipid nanoparticles for circRNA delivery with mannose surface modification, stability evaluation, and cell-based expression testing. | Inquiry |
| Mannose-LNP Development for gRNA/mRNA Combination | Supports co-loaded nucleic acid systems that require ratio control and particle uniformity. We evaluate co-encapsulation behavior, mannose-lipid compatibility, particle attributes, and functional readouts under matched control conditions. | Inquiry |
| Mannose-LNP Development for Protein and Peptide | Suitable for protein antigens, enzymes, peptides, binding proteins, and functional protein payloads used in immune-cell delivery research. Formulation work focuses on mild loading conditions, aggregation control, activity retention, and mannose-dependent uptake evaluation. | Inquiry |
| Mannose-LNP Development for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable small molecules used in macrophage or immune-cell delivery research. We consider drug-lipid compatibility, loading method, leakage control, particle stability, mannose modification, and release behavior. | Inquiry |
| Mannose-LNP Development for Fluorescent and Imaging | Supports fluorescent dyes, labeled RNA, labeled proteins, and other tracking payloads used to study mannose-LNP uptake, intracellular localization, biodistribution trends, and formulation comparison. | Inquiry |
| Mannose-LNP Development for Custom Payload | Developed for unusual payloads, multiple payload systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, mannose modification route, particle stability, and target-cell delivery performance. | Inquiry |
Mannose-LNP development often fails when ligand display, particle stability, payload loading, and target-cell biology are not optimized together. BOC Sciences helps solve these issues with data-guided formulation development.
✔ Weak Macrophage or DC Uptake Improvement
A mannose-LNP may show limited uptake improvement if the ligand is hidden by PEG, displayed at a poor density, or placed too close to the particle surface. We screen mannose-lipid structure, PEG linker length, ligand density, and PEG-lipid ratio to improve receptor-accessible presentation.
✔ Particle Size Increase After Mannose Modification
Mannose-lipid incorporation can disturb LNP assembly and cause larger particles or broad PDI. We rebalance helper lipid, cholesterol, ionizable lipid, PEG-lipid, and mannose-lipid content to restore particle uniformity.
✔ Reduced Payload Encapsulation
Surface modification can change the self-assembly environment needed for payload loading. We optimize lipid composition, aqueous phase pH, payload input, and process conditions for nucleic acids encapsulation in LNPs and other payload formats.
✔ Ligand Density and Stability Conflict
High mannose density may improve receptor interaction in some models, but too much surface modification can increase aggregation or reduce storage stability. We select candidates using particle data, ligand display data, and cell-based readouts together.
✔ Unclear CD206/MR Contribution
Macrophages can take up nanoparticles through several pathways. This makes mechanism analysis difficult. We design matched unmodified LNPs, mannose-LNP variants, receptor-different cell models, and competition assays to support clearer interpretation.
✔ High Uptake but Weak Payload Function
Strong uptake does not always lead to strong mRNA expression, siRNA knockdown, or protein activity. We evaluate RNA integrity, intracellular localization, endosomal release, and functional delivery to find the real bottleneck.
BOC Sciences helps research teams troubleshoot mannose ligand exposure, payload loading, particle instability, macrophage/DC uptake, CD206-related mechanism design, and functional delivery readouts.
We start by discussing your payload, target cell type, delivery goal, preferred readout, and expected LNP attributes. We also review whether your project focuses on macrophages, dendritic cells, APCs, Kupffer cells, or CD206+ TAM-like models. Based on these details, BOC Sciences prepares a practical mannose-LNP development plan.
We design a mannose surface strategy that fits your payload and target-cell model. The design may include mannose valency selection, PEG spacer optimization, lipid anchor selection, coupling method selection, and mannose density range planning. We also decide whether co-assembly, post-insertion, or surface coupling is the better route.
BOC Sciences prepares mannose-modified LNP candidates using suitable methods. During LNP process optimization, we adjust lipid composition, payload loading, mixing conditions, buffer exchange, ligand density, and particle stability. Matched unmodified LNP controls can also be prepared for comparison.
Each mannose-LNP candidate is evaluated for particle size, PDI, zeta potential, payload loading, ligand density, and formulation integrity. We can also support nanoparticle cellular uptake testing, intracellular localization, reporter expression, gene silencing, and distribution-related readouts in suitable research models.
Mannose-modified LNPs can be used for infectious disease vaccine development, tumor vaccine development, targeted gene therapy delivery, and related research. BOC Sciences helps researchers develop Mannose-Modified LNP systems for a wide range of applications based on different project goals.
Challenge: A research team was developing a mannose-modified LNP to deliver anti-inflammatory siRNA into macrophage models. The original mannose ligand showed weak stability during cell-based testing. The LNP also showed unstable uptake signals after incubation, making it difficult to connect mannose receptor interaction with downstream inflammatory marker reduction.
Diagnosis: BOC Sciences found that the ligand structure was one of the main bottlenecks. The original O-glycosidic mannose design was not stable enough for the planned macrophage uptake study. At the same time, the PEG-lipid level partly shielded the mannose ligand, which reduced receptor-accessible display on the LNP surface.
Solution: BOC Sciences redesigned the ligand as a thio-mannose structure to improve metabolic stability. We then compared this ligand with the original mannose-lipid in a matched LNP formulation. The formulation screen included mannose density, PEG-lipid ratio, and ionizable lipid balance. Candidate LNPs were evaluated by particle size, PDI, siRNA encapsulation, Con A-FITC binding, macrophage uptake, and anti-inflammatory siRNA activity.
Result: The selected thio-mannose LNP maintained an average particle size of about 105 nm and showed a PDI below 0.22. siRNA encapsulation remained above 80%, and the inflammatory marker signal decreased by about 55% in the selected macrophage model. The client obtained a more stable mannose-LNP candidate for anti-inflammatory siRNA delivery research.
Challenge: A biotechnology group wanted to deliver antimicrobial peptide mRNA into dendritic cell and macrophage-related models. Their first monovalent mannose-LNP showed measurable uptake, but the mRNA expression level was low. The team needed a ligand design with stronger receptor interaction and better functional delivery.
Diagnosis: BOC Sciences reviewed the ligand architecture and found that the monovalent mannose display was not strong enough for the target-cell model. The formulation also needed better spacing between the mannose ligand and the LNP surface so that the receptor could access the ligand more easily.
Solution: BOC Sciences designed a four-lysine scaffold-based trivalent mannose ligand. This multivalent ligand was selected to improve mannose receptor interaction by about 100-fold compared with the monovalent design. We prepared mannose-LNP candidates with different ligand densities and PEG spacer lengths, then assessed particle quality, mRNA integrity, target-cell uptake, and antimicrobial peptide expression.
Result: The optimized trivalent mannose-LNP kept the average particle size around 115 nm and maintained mRNA encapsulation above 75%. Target-cell uptake increased by about 2-fold compared with the monovalent mannose-LNP. The client received a clearer formulation direction for antimicrobial peptide mRNA delivery into immune-cell models.
Integrated LNP Development ExperienceBOC Sciences has practical experience in lipid nanoparticle formulation, payload loading, surface engineering, particle characterization, and functional delivery evaluation. This helps clients develop mannose-LNPs with better design logic and clearer data.
Strong Mannose Surface Engineering CapabilityWe support mannose ligand selection, mannose-lipid synthesis, PEG spacer design, lipid anchor selection, multivalent mannose display, and ligand density optimization for CD206/MR-related delivery research.
Payload-Compatible Formulation DesignDifferent payloads need different LNP strategies. BOC Sciences designs mannose-modified formulations for RNA, protein, peptide, small molecule, imaging, and custom payload systems.
Clear Targeting Validation DesignWe help clients compare mannose-LNPs with unmodified controls and related formulation variants. This makes it easier to understand whether mannose modification improves uptake, localization, and payload function.
Flexible Support for Custom Mannose-LNP ProjectsBOC Sciences supports feasibility testing, formulation screening, ligand density optimization, process adjustment, control LNP preparation, and macrophage/DC-related delivery evaluation according to each project goal.
Mannose-modified LNPs are mainly designed to enhance delivery toward mannose receptor-expressing cells, including macrophages, dendritic cells, antigen-presenting cells, Kupffer cells, and CD206+ tumor-associated macrophage models. By displaying mannose ligands on the LNP surface, these nanoparticles can improve receptor-related recognition and cellular uptake compared with non-modified LNPs. This strategy is particularly useful for projects involving immune-cell delivery, macrophage modulation, dendritic cell uptake, tumor microenvironment research, and inflammation-related models. The final targeting effect depends on mannose ligand structure, surface density, PEG spacer length, particle size, and the biological features of the selected cell model.
Mannose ligand density needs to be carefully balanced rather than simply maximized. Low ligand density may not provide enough receptor interaction, while excessive mannose display can disrupt LNP self-assembly, increase particle size, broaden PDI, or reduce payload retention. A practical optimization strategy usually compares low, medium, and high mannose density levels together with different PEG spacer lengths, lipid anchors, and core lipid ratios. BOC Sciences can evaluate particle size, PDI, zeta potential, payload loading, surface mannose display, and macrophage or dendritic cell uptake to identify formulations that maintain both receptor accessibility and nanoparticle stability.
Mannose-modified LNPs can be developed for diverse payloads, including siRNA, mRNA, circRNA, gRNA/mRNA combinations, proteins, peptides, small molecules, fluorescent labels, and imaging payloads. Each payload type requires a different formulation strategy. RNA payloads often need strong encapsulation, integrity protection, and functional expression or silencing readouts. Protein and peptide payloads require mild loading conditions and activity retention. Small molecules need compatibility assessment with the lipid phase and leakage control. Because mannose modification may change the particle surface and self-assembly behavior, payload loading, ligand display, and target-cell delivery performance should be optimized together.
Mannose-LNP uptake should be validated with well-designed controls rather than relying only on stronger fluorescence signals. Common approaches include comparing unmodified LNPs with mannose-modified variants, testing multiple mannose densities, using CD206/MR-high and low-expression cell models, and adding free mannose competition or receptor-blocking designs when suitable. Flow cytometry can quantify uptake levels, while confocal imaging can show intracellular localization. Functional readouts such as mRNA expression, siRNA knockdown, protein activity, or cytokine-related marker changes can help determine whether increased uptake leads to useful payload delivery. This distinction is important because high nanoparticle uptake does not always mean strong functional delivery.
BOC Sciences supports mannose-modified LNP development from ligand strategy to formulation screening, characterization, and target-cell evaluation. For early-stage projects, BOC Sciences can help compare monovalent mannose, multivalent mannose clusters, PEG linker lengths, lipid anchors, and surface incorporation methods. For projects with existing formulation challenges, the team can troubleshoot weak uptake improvement, particle size increase, broad PDI, reduced payload loading, unclear CD206/MR contribution, or high uptake with weak functional output. By integrating LNP formulation experience with mannose surface engineering and macrophage/DC-related testing, BOC Sciences helps researchers build clearer, more stable, and more target-oriented mannose-LNP systems.
